Skip to contentG
Gilead Sciences, Inc.
G
GILDGilead Sciences, Inc. Q1 2021 · 10-Q
Revenue$6.42B$6.42B+15.8% vs Q1 2020 Net Income$1.73B$1.73B+11.5% vs Q1 2020 EPS Diluted$1.37$1.37+12.3% vs Q1 2020 Operating Income$2,890,000,000+20.3% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
Free Cash Flowderived$2,445,000,000+93.3% Margins · derivedOperating margin45.0%+1.7 pt vs Q1 2020
Net margin26.9%−1.0 pt vs Q1 2020
ended Mar 31, 2021 · filed May 6, 2021 · 36 d after period end